Robert Chunhua Zhao，M.D. PhD
Fellow, European Academy of Sciences, Arts and Humanities (EASAL)
Cheung Kong Scholar
Tenured Professor，Chinese Academy of Medical Sciences and Peking Union Medical College
Director, Center for Excellence in Tissue Engineering，Chinese Academy of Medical Sciences；
Director, Beijing Key Laboratory of New Drug Development and Clinical Trial of Stem Cell Therapy
Dean, School of Life Sciences, Shanghai University
President, International Society on Aging and Disease (ISOAD)
Robert Chunhua Zhao has been committed to stem cell biology, pharmacy, and clinical application for more than 30 years. He is the chief scientist of projects such as the National 973 Program, 863 Program, National Key R&D Program, etc. He has internationally proposed the concept of “Post-embryonic pluripotent stem cell theory”. He has published over 400 papers in international and domestic journals, with an H-index of 71. And from 2014 to 2022, he has been selected as a highly cited China scholar by Elsevier for 9 consecutive years. In 2004 his group won the first official approval of “mesenchymal stem cell” from SFDA as to start clinical trials in China. He was awarded the 1st Prize of Technological Invention from MOE and the 2nd Prize of National Technological Invention. He has established a translational medical system that integrates basic theories of integrated stem cells, key scientific technologies, and clinical trial treatment research.